Biomarkers of Adverse Cardiovascular Events in Chronic Coronary Disease: Data From the ISCHEMIA Trial

被引：0
|
作者：
Newman, Jonathan D.
Ruggles, Kelly V.
Cornwell, Macintosh
Anthopolos, Rebecca
Held, Claes
Kullo, Iftikhar J.
Newby, L. Kristin K.
McManus, Bruce M.
Bangalore, Sripal
Reynolds, Harmony R.
Hochman, Judith S.
Maron, David J.
Berger, Jeffrey S.
机构：
来源：
CIRCULATION | 2022年 / 146卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13582
引用
收藏
页数：3
相关论文
共 50 条
  • [31] IS THE HIGH 6 MONTH REOCCLUSION RATE FOLLOWING SUCCESSFUL PICA OF CHRONIC CORONARY OCCLUSIONS ASSOCIATED WITH ADVERSE CARDIOVASCULAR EVENTS - RESULTS FROM THE MARCATOR TRIAL
    BERGER, PB
    OHMAN, EM
    OHANESIAN, MA
    MURPHY, J
    BELL, MR
    FAXON, DP
    CIRCULATION, 1995, 92 (08) : 1644 - 1644
  • [32] Novel Biomarkers/Predictors of Cardiovascular Disease and Cardiovascular Events
    Paraskevas, Kosmas I.
    Jezovnik, Mateja K.
    Poredos, Pavel
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (04) : 444 - 447
  • [33] Prediction of long-term adverse cardiovascular events after percutaneous coronary interventions in patients with coronary artery disease and concomitant chronic obstructive pulmonary disease
    Zafiraki, V. K.
    Skaletskiy, K. V.
    Namitokov, A. M.
    Shulzhenko, L. V.
    Kosmacheva, Ye. D.
    Pershukov, I. V.
    KARDIOLOGIYA, 2020, 60 (05) : 115 - 122
  • [34] EFFECT OF CHELATION THERAPY ON CARDIOVASCULAR EVENTS BY CHRONIC KIDNEY DISEASE STAGE: DATA FROM THE TRIAL TO ASSESS CHELATION THERAPY (TACT)
    Ouyang, Pamela
    Lamas, Gervasio
    Nahin, Richard
    Gallup, Dianne
    Boineau, Robin
    Rosenberg, Yves
    Mark, Daniel
    Goertz, Christine
    Lee, Kerry
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1537 - A1537
  • [35] INDUCIBLE MYOCARDIAL ISCHEMIA AND HIGH-SENSITIVITY TROPONIN I ADDITIVELY PREDICT ADVERSE CARDIOVASCULAR EVENTS IN STABLE CORONARY ARTERY DISEASE
    Kim, Jeong Hwan
    Hammadah, Muhammad
    Lima, Bruno
    Liu, Chang
    Ko, Yi-An
    Sullivan, Samaah
    Moazzami, Kasra
    Beshiri, Agim
    Murtagh, Gillian
    Alkhoder, Ayman
    Martini, Afif
    Ward, Laura
    Bremner, Doug
    Shah, Amit
    Pearce, Brad D.
    Garcia, Ernest
    Raggi, Paolo
    Vaccarino, Viola
    Quyyumi, Arshed
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 119 - 119
  • [36] Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
    Karady, Julia
    Mayrhofer, Thomas
    Foldyna, Borek
    Lu, Michael T.
    Meyersohn, Nandini
    Hoffmann, Udo
    Balogon, Oluwafemi
    Pagidipati, Neha
    Shah, Svati
    Douglas, Pamela S.
    Ferencik, Maros
    Corey, Kathleen
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (03) : 558 - 569
  • [37] Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease
    von Haehling, Stephan
    Papassotiriou, Jana
    Morgenthaler, Nils G.
    Hartmann, Oliver
    Doehner, Wolfram
    Stellos, Konstantinos
    Wurster, Thomas
    Schuster, Andreas
    Nagel, Eike
    Gawaz, Meinrad
    Bigalke, Boris
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 162 (01) : 27 - 32
  • [38] Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease
    Wheeler, Matt
    Chan, Noel
    Eikelboom, John
    FUTURE CARDIOLOGY, 2020, 16 (06) : 597 - 612
  • [39] Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease
    Meyersohn, Nandini M.
    Mayrhofer, Thomas
    Corey, Kathleen E.
    Bittner, Daniel O.
    Staziaki, Pedro V.
    Szilveszter, Balint
    Hallett, Travis
    Lu, Michael T.
    Puchner, Stefan B.
    Simon, Tracey G.
    Foldyna, Borek
    Voora, Deepak
    Ginsburg, Geoffrey S.
    Douglas, Pamela S.
    Hoffmann, Udo
    Ferencik, Maros
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (07) : 1480 - +
  • [40] Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
    Agushi, Erjon
    Xhyheri, Borejda
    Bugiardini, Raffaele
    CURRENT VASCULAR PHARMACOLOGY, 2013, 11 (05) : 785 - 794
12345